Oct. 5 (Bloomberg) -- Evotec AG entered into a second multi-year, multi-target drug discovery cooperation with UCB SA in the field of immunology. Evotec will identfy small molecules against a selected number of targets.

Evotec will receive research funding based on the resource allocated over the projects and will be further rewarded on achieving the goals with early stage discovery, preclinical and clinical milestones. Evotec will also receive royalties based on net sales of any approved drugs.

Link to Statement:{NSN LSKVAU3PR6RK <GO>}

To contact the editor responsible for this story: Mariajose Vera at mvera1@bloomberg.net